Phanes Therapeutics is an innovative biotech company with a strong preclinical pipeline in oncology and eye disease. In addition, we have built a proprietary technology platform for constructing bispecific antibodies: PAC . We have established licensing partnerships with Hanmi Pharmaceutical Co., Ltd. and Fosun Kite Biotechnology Co., Ltd. with our proprietary molecules. For details, please read more here.
We are currently seeking partnerships with companies focused on clinical development and commercialization to advance our programs by leveraging both companies’ strengths. We are also seeking partners that are interested in leveraging our PAC platform to build and advance bispecific antibodies for various indications.